SCHEMBL5438576

SCHEMBL5438576

O=c1[nH]c(=S)c2nccnc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ LMNA P02545 1/20 0.36
▸ GDA Q9Y2T3 2/20 0.34
▸ ACHE P22303 1/20 0.34
▸ GSK3A P49840 3/20 0.32
▸ GSK3B P49841 3/20 0.32
▸ CDK5 Q00535 3/20 0.32
▸ TYRO3 Q06418 2/20 0.32
▸ DYRK1B Q9Y463 2/20 0.32
▸ AURKA O14965 1/20 0.32
▸ DAPK3 O43293 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ PRKD3 O94806 1/20 0.32
▸ MAP4K4 O95819 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ NTRK1 P04629 1/20 0.32
▸ FYN P06241 1/20 0.32
▸ RET P07949 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5438414 0.78 TDP1 (0.45) KDM4EALDH1A1LMNAGSK3AGSK3B
SCHEMBL29545868 0.78 KDM4E (0.46) KDM4EALDH1A1LMNAGDAACHE
SCHEMBL932546 0.78 KDM4E (0.46) KDM4EALDH1A1LMNAGDAACHE
Hydrochloric Acid SCHEMBL28868510 0.77 KDM4E (0.44) KDM4EALDH1A1LMNAGDAACHE
Water SCHEMBL6479622 0.77 KDM4E (0.44) KDM4EALDH1A1LMNAGDAACHE
Hydrochloric Acid SCHEMBL30431695 0.77 KDM4E (0.44) KDM4EALDH1A1LMNAGDAACHE
SCHEMBL30572345 0.77 GDA (0.44) KDM4EALDH1A1GDAACHEGSK3A
SCHEMBL3961933 0.77 GDA (0.44) KDM4EALDH1A1GDAACHEGSK3A
SCHEMBL340668 0.77 GDA (0.44) KDM4EALDH1A1GDAACHEGSK3A
Hydrochloric Acid SCHEMBL3957661 0.74 GDA (0.43) KDM4EALDH1A1GDAACHEGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 — — EP claimed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 — — WO claimed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 — — EP claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 — — US claimed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 — — US disclosed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 — — US disclosed
WO-2006052660-A9 IL-7 RECEPTOR BLOCKADE TO SUPPRESS IMMUNITY LOS ANGELES CHILDRENS HOSPITAL (US) 2006-08-31 — — WO disclosed
WO-2006052660-A2 IL-7 RECEPTOR BLOCKADE TO SUPPRESS IMMUNITY CHILDRENS HOSPITAL LOS ANGELES RESEARCH INSTITUTE (US) 2006-05-18 — — WO disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 — — EP disclosed
EP-1636232-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-03-22 — — EP disclosed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 — — US disclosed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 — — US disclosed
WO-2004104005-A3 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-01-27 — — WO disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 — — WO disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 — — WO disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 — — EP disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 — — EP disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 — — US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1686/4885ALDH1A1 1767/4885LMNA 3813/4885
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1278/4885ALDH1A1 1744/4885LMNA 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback